US Patent 11357820 GIP/GLP1 agonist compositions
Patent 11357820 was granted and assigned to Eli Lilly and Company on June, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113578200
Date of Patent
June 14, 2022
0Patent Application Number
164413290
Date Filed
June 14, 2019
0Patent Primary Examiner
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113578200
Date of Patent
June 14, 2022
0Patent Application Number
164413290
Date Filed
June 14, 2019
0Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+17 properties)
Article (+132 characters)
US Patent 11357820 GIP/GLP1 agonist compositions
Article
A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11357820
Date of patent
June 14, 2022
Patent application number
16441329
Date Filed
June 14, 2019
Patent primary examiner
Find more entities like US Patent 11357820 GIP/GLP1 agonist compositions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.